07:00 , Aug 1, 2016 |  BC Week In Review  |  Clinical News

AGT-182: Phase I/IIa data

Data from the first cohort of 4 Hunter syndrome patients ages >=18 in the open-label, international Phase I/IIa Breaking Barriers trial showed that once-weekly 1 mg/kg IV AGT-182 for 8 weeks was generally well tolerated....
08:00 , Jan 18, 2016 |  BioCentury  |  Strategy

Shire's serial story

The most obvious benefits Shire plc expects to gain by acquiring Baxalta Inc. are a slew of new products and the cash to make subsequent acquisitions the company couldn't have made on its own. But...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Company News

ArmaGen, Shire deal

ArmaGen Inc. (formerly ArmaGen Technologies Inc.) received an undisclosed milestone payment from Shire under a 2014 deal granting Shire rights to AGT-182 . The milestone was triggered by the start of patient dosing in a...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

AGT-182: Phase I started

ArmaGen began an open-label, dose-escalation, U.S. Phase I trial to evaluate 1 and 3 mg/kg IV AGT-182 once weekly for 8 weeks in about 12 patients. The trial start triggered an undisclosed milestone payment to...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Company News

Shire, ArmaGen deal

ArmaGen granted Shire exclusive, worldwide rights to develop and commercialize AGT-182 , which is in development to treat mucopolysaccharidosis type II (MPS-II, Hunter’s syndrome). ArmaGen will receive $15 million up front in cash and equity....
07:00 , Jul 28, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained $5.79 to $167.04 last week after EMA accepted and granted accelerated assessment to an MAA for asfotase alfa to treat hypophosphatasia (HPP). The company expects to complete a...
00:58 , Jul 24, 2014 |  BC Extra  |  Company News

ArmaGen licenses AGT-182 to Shire

ArmaGen Technologies Inc. (Calabasas, Calif.) granted Shire plc (LSE:SHP; NASDAQ:SHPG) exclusive, worldwide rights to develop and commercialize AGT-182 , which is in development to treat mucopolysaccharidosis type II (MPS-II, Hunter's syndrome). ArmaGen will receive $15...
07:00 , Jun 16, 2014 |  BioCentury  |  Regulation

Signal crossing

FDA...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Clinical News

AGT-182 regulatory update

The European Commission granted Orphan Drug designation to AGT-182 from ArmaGen to treat mucopolysaccharidosis type II (MPS-II, Hunter's syndrome). The product is slated to enter clinical testing for MPS-II this half and has Orphan Drug...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Clinical News

AGT-182 regulatory update

ArmaGen said FDA granted Orphan Drug designation for AGT-182 to treat mucopolysaccharidosis type II (MPS-II, Hunter's syndrome). The product is slated to enter clinical testing for MPS-II next half. AGT-182 is iduronate-2-sulfatase (IDS) formulated with...